key: cord-1036857-uesdvvtc authors: Vallée, Alexandre; Lecarpentier, Yves; Vallée, Jean-Noël title: Interplay of Opposing Effects of the WNT/β-Catenin Pathway and PPARγ and Implications for SARS-CoV2 Treatment date: 2021-04-13 journal: Front Immunol DOI: 10.3389/fimmu.2021.666693 sha: 619f032f98c22fe913c472fa03135d0fe0bd6da8 doc_id: 1036857 cord_uid: uesdvvtc The Coronavirus disease 2019 (COVID-19), caused by the novel coronavirus SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), has quickly reached pandemic proportions. Cytokine profiles observed in COVID-19 patients have revealed increased levels of IL-1β, IL-2, IL-6, and TNF-α and increased NF-κB pathway activity. Recent evidence has shown that the upregulation of the WNT/β-catenin pathway is associated with inflammation, resulting in a cytokine storm in ARDS (acute respire distress syndrome) and especially in COVID-19 patients. Several studies have shown that the WNT/β-catenin pathway interacts with PPARγ in an opposing interplay in numerous diseases. Furthermore, recent studies have highlighted the interesting role of PPARγ agonists as modulators of inflammatory and immunomodulatory drugs through the targeting of the cytokine storm in COVID-19 patients. SARS-CoV2 infection presents a decrease in the angiotensin-converting enzyme 2 (ACE2) associated with the upregulation of the WNT/β-catenin pathway. SARS-Cov2 may invade human organs besides the lungs through the expression of ACE2. Evidence has highlighted the fact that PPARγ agonists can increase ACE2 expression, suggesting a possible role for PPARγ agonists in the treatment of COVID-19. This review therefore focuses on the opposing interplay between the canonical WNT/β-catenin pathway and PPARγ in SARS-CoV2 infection and the potential beneficial role of PPARγ agonists in this context. The Coronavirus disease 2019 , caused by the novel coronavirus SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), has quickly reached pandemic proportions. Like SARS-CoV, SARS-CoV-2 is a member of the Beta-coronavirus family. Although the majority of COVID-19 patients present mild to moderate clinical features (1, 2) , some may develop severe pneumonia or suffer from the acute respiratory distress syndrome (ARDS) and multi-organ failure, leading to high death rates. Nevertheless, the pathophysiology of Corona Virus Disease-19 (COVID-19) remains unclear. Currently, in patients with life-threatening ARDS, there is growing evidence that virally-induced pro-inflammatory cytokines (such as Interleukin (IL)-6 and tumor necrosis factor-a (TNF-a)) enhance inflammation in the latter stages of this disease (3) (4) (5) . Such findings are further corroborated by recent studies indicating that high levels of IL-6 are predictors of mortality (6) . Cytokine profiles in COVID-19 patients have revealed increased levels of interleukin-1b (IL-1b), IL-2, IL-6 and tumor necrosis factor-alpha (TNFa) (7) . TNF-a is one of the main activators of IL-6 expression and an increase in baseline plasma levels of IL-6 may predict that survival chances are poor (7) . Moreover, an increase in the proportion of Th17 cells has been observed in COVID-19 patients, leading to the stimulation of IL-6 (8) . Recent evidence has shown that the upregulation of the canonical WNT/b-catenin pathway is associated with inflammation and a cytokine storm in ARDS (9) and especially COVID-19 patients (10) . Several studies have shown that, in numerous diseases (11) (12) (13) (14) , the WNT/b-catenin pathway interacts with PPARg (peroxisome proliferator-activated receptor gamma) in an opposing interplay, with the effects of one opposing those of the other. Recent studies have also highlighted the possible role of PPARg agonists as modulators of inflammatory and immunomodulatory drugs by targeting the cytokine storm in COVID-19 patients (15, 16) . This review focuses on the opposing interplay between WNT/b-catenin and PPARg in SARS-CoV-2 infection and the potential role of PPARg agonists in this context. The severity of symptoms in SARS-CoV-2 infection depends on the viral infection and the host immune system. The COVID-19 cytokine profile of patients is closely associated with cytokine release, indicating macrophage activation, and an increase in the level of cytokines such as the TNFa, IL-6 and interferon-gamma (IFN-g) (4). The increased levels of these cytokines is a characteristic of ARDS, with a low level of oxygen in the blood and shortness of breath (17) . The SARS-CoV-2 infection mainly damages the endothelial cells of the airway, alveoli, vascular system, and macrophages in the lungs. SARS-CoV-2 recruits the receptor of angiotensin-converting enzyme 2 (ACE2) for infection (18) . The expression of the ACE2 receptor is decreased in the lungs in the SARS-CoV-2 infection, dysregulating the renin-angiotensin system, which damages the fluid and electrolyte balance, blood pressure levels, and increases the vascular permeability and inflammatory processes in the airway (19) (20) (21) . SARS-CoV recruits several immune-suppressive proteins thereby increasing the immune response (22) . SARS-CoV enhances several structural and non-structural proteins acting as antagonists of interferon signaling. Stopping interferon signaling could be a response to: a) prevent the recognition of viral RNA via the pattern recognition receptor (PRR), b) decrease the synthesis of type I interferon protein by interrupting the toll-like receptor-1 (TLR-1) and the retinoic acid-inducible gene I (RIG-I), and c) increase the STAT pathway activity (23) . The SARS-CoV-2 virus causes massive damage to the infected epithelial and endothelial cells, with an excessive release of cytokines and chemokines (18) . In SARS-CoV-2, stimulation of the caspase-1 enhances the production of pro-inflammatory cytokines such as IL-1b and IL-6 (24). These cytokines bind with other immune cells, including T-lymphocytes and monocytes (8, 25) . Severe COVID-19 patients show increased levels of the granulocyte colony-stimulating factor (G-CSF), IL-2, IL-6, IL-10, monocyte chemo-attractant peptide (MCP)-1), macrophage inflammatory protein 1a (MIP1a) and TNF-a (26) . The nuclear factor-kB (NF-kB) pathway is one of the main inflammation processes. NF-kB is a hetero-dimeric transcription factor belonging to the Rel protein family. Under physiological conditions, RelA/p50, the heterodimer's predominant form of the NF-kB pathway, is inactivated in the cytoplasm by the IkB protein (27) . SARS-CoV infection leads to a release of proinflammatory cytokines and growth factors to activate the IkB Kinase (IKK), which phosphorylates and degrades the IkB protein through an ubiquitination mechanism (28) . The NF-kB pathway can modulate the expression of proinflammatory genes responsible for the cytokine storm. SARS-CoV-2 can induce the nuclear translocation of the NF-kB pathway to stimulate IL-6 expression (28) . Numerous studies have shown that SARS-CoV (29) (30) (31) , including SARS-Cov-2 (32), can activate the NF-kB pathway. The name WNT is derived from Wingless drosophila melanogaster and its mouse homolog Int. The canonical WNT/ b-catenin pathway is involved in several mechanisms, controlling signaling, including embryogenesis, cell proliferation, migration and polarity, apoptosis, and organogenesis (33) . Nevertheless, the WNT/b-catenin pathway can be altered in several pathological diseases, such as inflammation, metabolic, neurological and psychiatric disorders, fibrosis and cancer processes (34) (35) (36) (37) (38) (39) (40) (41) (42) . The WNT ligands belongs to the family of secreted lipidmodified glycoproteins (43) . WNT ligands are produced by neurons and immune cells localized in the central nervous system (CNS) (44) . WNT pathway dysfunction can affect numerous neurodegenerative pathologies (11, (45) (46) (47) (48) . The canonical WNT pathway comprises the b-catenin, T-cell factor and lymphoid enhancer factor (TCF/LEF). Cytoplasmic accumulation of b-catenin is modulated by the destruction complex AXIN, tumor suppressor adenomatous polyposis coli (APC), and glycogen synthase kinase-3 (GSK-3b). In the absence of WNT ligands, the destruction complex has a role in the phosphorylation of the cytoplasmic b-catenin and leads to its proteasomal destruction. However, when they are present, WNT ligands bind with Frizzled (FZL) and LDL receptor-related protein 5/6 (LRP 5/6) to interrupt the destruction complex and prevent bcatenin degradation into the proteasome. b-catenin translocates to the nucleus to interact with the TCF/LEF. This stimulates the WNT target genes (49) (50) (51) . Glycogen synthase kinase-3b (GSK-3b) is one of the major inhibitors of the WNT/b-catenin pathway (35, 36, (52) (53) (54) (55) . As an intracellular serine-threonine kinase, GSK-3b is a major negative controller of WNT signaling (56) . GSK-3b is involved in the control of numerous kinds of pathophysiological pathways, including cell membrane signaling, cell polarity, and inflammation (57) (58) (59) . GSK-3b interacts by downregulating the cytoplasmic b-catenin and stabilizing it to enhance its nuclear migration (60) . A positive interplay has been recently observed between the WNT/b-catenin pathway and inflammation, expressed by an activated NF-ϰB pathway (37) . Over-stimulation of WNT/bcatenin leads to the enhancement of IϰB-a degradation and then NF-ϰB pathway transactivation (61) . The WNT/b-catenin pathway increases COX expression, which then influences the inflammatory response (62) . In addition, the NF-ϰB pathway downregulates GSK-3b and positively enhances b-catenin signaling (63, 64) . Several studies have shown that WNT ligands, secreted by immune cells, can control inflammatory response and immune cell modulation (65) (66) (67) (68) . Moreover, WNT ligands play major roles in tissue damage and repair (65) . The WNT/b-catenin pathway is upregulated in severe sepsis-induced acute lung injury and sepsis mouse models (67, 69) . The WNT pathway is damaged in sepsis or ARDS, and therefore plays a major role in fibrosis and inflammation (66, 70) . In COVID-19 patients, the transforming growth factor (TGF-b) stimulates the WNT/b-catenin pathway, leading to an increased risk of pulmonary fibrosis (70) and pulmonary infection (10, 71) ( Table 1) . Several studies have shown that the TGF-b and WNT/b-catenin pathways upregulate each other in a positive feedback (54, 88) . The TGF-b pathway is one of the main signaling pathways involved in fibrosis through the enhancement of EMT and fibroblast differentiation (89) . Several inflammatory cytokines have a positive relationship with the TGF-b pathway (89) . Interactions between the TGF-b pathway and Smad pathway are involved in pulmonary fibrosis (90) . The TGF-b/Smad pathway has been shown to be a promotor of PAI-1 synthesis in SARS-CoV (91) . Moreover, cytokines can activate the JAK/ STAT pathway (92) to dysregulate cellular homeostasis, proliferation and apoptosis (93) . IL-6 can activate the JAK/ STAT pathway in T helper cells (4, 94) to induce several biological functions, such as immune regulation, lymphocyte differentiation and oxidative stress (72, 95) . The increase in IL-6 observed in severe COVID-19 patients is associated with significantly lower survival rates (6, 96) . COVID-19 patients present both dysregulated JAK/STAT pathway (97) and important role of TGF-b/Smad pathway (98) . In severe COVID-19 patients, serum IL-6 is significantly greater than in non COVID-19 subjects (99) . The excessive production of inflammatory cytokines in the lungs of COVID-19 patients is associated with the increase in macrophage activation (100) . In a mouse model of systemic inflammation, PAI-1 is involved in the regulation of host inflammatory responses through Toll-like Receptor-4 (TLR4)-mediated macrophage activation (101) . Activation of the NF-kB pathway results in stimulating the TGFb pathway in a vicious loop (73) and in concordance with PAI-1 (74) . Thus, PAI-1 seems to be partly responsible for the excessive production of cytokines by macrophages in severe COVID-19 patients (75) . PAI-1 expression is associated with increased IL-10 and an activated TGF-b pathway (102) . Thus, the activated TGF-b pathway observed in COVID-19 patients may drive the pulmonary fibrosis process (102). In COVID-19 patients, ECM dysregulation could be one of the sources of stimulation of the TGF-b pathway (76, 103) ( Table 1) . This stimulation is responsible for the activation of integrin avb6 and thrombospondin induced by the STAT pathway (76, 104) . In COVID-19 patients, a vicious loop is involved between the TGF-b pathway, the STAT pathway and PAI-1 (75) . Furthermore, the targets involved in fibrosis, such as collagens, proteoglycans, integrins, the connective tissue growth factor, and matrix metalloproteinases (MMPs) are activated by the TGF-b pathway (105) . SARS-CoV proteins may enhance the TGFb-induced expression of PAI-1 and collagen I to induce lung fibrosis (106). PPARs (peroxisome proliferator-activated receptors) are ligandactivated transcription factors that bind PPREs (PPAR-response elements). In the nucleus, PPARs form a heterodimer with the retinoid X receptor (RXR) (107) . They are composed of a ligandbinding domain that interacts with a DNA-binding domain to modulate it (108) . PPARs are involved in numerous pathophysiological processes, such as cell differentiation, protein metabolism, lipid metabolism, carcinogenesis (109, 110) , adipocyte differentiation, insulin sensitivity and inflammation (111, 112) . PPARs are subdivided into three isoforms: PPARa, PPARg and PPARb (113) . PPARg is highly expressed in adipose tissue and macrophages (114) . PPARg ligands can be synthetic or natural. PPARg ligands have hypoglycemic and hypocholesterolemic roles. PPARg agonists such as thiazolidinediones (TZDs) have been used to treat type 2 diabetes patients (115) and to decrease inflammatory activity (115) . Natural ligands include prostaglandins and unsaturated fatty acids (116) . Natural ligands include prostaglandins and unsaturated fatty acids. Moreover, PPARg ligands, such as thiazolidinediones, can directly decrease inflammatory activity (12) , fibrosis processes (117) and lung inflammation (118) . In adipocyte mitochondria, pioglitazone (30-45 mg/day for three months) can reduce the expression of cytokines, including IL-6 and TNFa in humans (119) . In patients with impaired glucose tolerance, four months (45 mg/day) of treatment with pioglitazone is associated with a reduction of monocyte IL-1, IL-6, IL-8 and lymphocyte IL-2, IL-6 and IL-8 (120) . Pioglitazone has also shown a potential for decreasing ferritin in a rat model of angiotensin II-induced hypertension (121) . Moreover, pioglitazone can decrease the secretion of proinflammatory cytokines (IL-1b, IL-6, and IL-8) and increase the anti-inflammatory ones (e.g. IL-4 and IL-10) in astrocytes stimulated by lipopolysaccharide (122) . Pioglitazone (treatment for 7 days) could decrease TNFa and IL-6 mRNA expression in the peritoneal lavage fluid (15, 123) . Furthermore, pioglitazone is a wellknown inhibitor of lung inflammation and fibrosis (118) , through normalization of the expression of TNF-a (124) . Pioglitazone and rosiglitazone use can reduce both the increase in inflammatory markers and the decrease in the glutamate transporter (GLT-1) expression, in a primary mixed culture of astrocytes and microglia caused by exposure to in vitro viral proteins (HIVADA gp120) and in vivo models (125) . Pioglitazone can decrease the neuroinflammation and maintain mitochondrial respiration (126) . The use of pioglitazone has also produced encouraging results in the form of decreasing CRP and IL-6 levels (127) . In animal studies, pioglitazone has been shown to decrease mortality from sepsis and lung injury by reducing inflammatory cytokine production in omental tissue (123) . Several studies have shown that the canonical WNT/b-catenin pathway and PPARg act in an opposing manner in numerous disorders, including cancers, neurodegenerative diseases, psychiatric disorders and fibrosis processes (47, 117, 128) . In many diseases, PPARg expression is downregulated by b-catenin signaling over-activation (12, 13, 48, (129) (130) (131) . PPARg agonists are considered to offer promising treatment through this crosstalk process (13, 132, 133) . Indeed, PPARg is considered to be a negative b-catenin target gene (134, 135) . The WNT/bcatenin pathway and PPARg interact through a TCF/LEF domain of b-catenin and a catenin-binding domain within PPARg (77, 136) . Through this link, a decrease in WNT/bcatenin pathway activity enhances the activation of PPARg (78), while PPARg over-expression inhibits b-catenin signaling (79). SARS-CoV-2 uses the angiotensin-converting enzyme 2 (ACE2) as a main cell receptor to infect humans (80, 137-139) ( Table 1) . ACE2 plays a leading role in the regulation of cardiovascular and renal functions (140) and has also been shown to have a major role in SARS-CoV-2 infection (80, 138) . SARS-CoV-2 may invade human organs besides the lungs through the expression of ACE2 (141) . Recent findings have revealed that ACE2 is downregulated in SARS-CoV-2-infected lung tissue (142) . Evidence from studies has shown that SARS-CoV-2 gains direct access to cells through ACE2 receptors (80, 143) , as happens with SARS-CoV (144) . SARS-CoV-2 infection leads to the downregulation of the expression of ACE2 by binding with the spike (S) viral protein -1273 amino acid long protein (145) . The pivotal role of ACE2 is its degradation of angiotensin II into angiotensin 1-7 (146) . This degradation mechanism is blocked by a selective ACE2 inhibitor, such as MLN-4760 (147) . A recent study focusing on SARS-CoV-2 has shown that angiotensin II accumulation leads to fibrosis, endothelial dysfunction, increased inflammation and oxidative stress (81) . Moreover, angiotensin II is associated with macrophage activation and both IL-6 and TNF-a overexpression (148) . Furthermore, the deficiency in ACE2 could exacerbate outcomes in COVID-19 patients (148) . In COVID-19 patients, ACE2 expression is inversely associated with the WNT/b-catenin and TGF-b pathways (141) . ACE2 presents a positive association with PD-L1, a predictive marker for active response to immune inhibitors (142) . The stimulation of ACE2 allows it to play a major protective role in the treatment of hypertension, heart disease, cancer and COVID-19 (141) , which are all disorders that show an upregulation of the WNT/b-catenin pathway. Rats with renal ischemia/reperfusion-induced injury treated by pioglitazone have shown a downregulated WNT/b- catenin pathway and increased ACE2 expression (82) . Even though very few studies have so far highlighted the possible role of PPARg agonists in treating COVID-19 patients, rosiglitazone has been shown to increase ACE2 expression in animal models (81) and it could also potentially be used in diabetic patients with COVID-19 (85) . To date, few studies have focused on the potentially interesting link between PPARg agonists and the development of COVID-19. The role of these agonists in SARS-CoV-2 infection therefore remains hypothetical (15, 16) (Table 1) . Currently, no clinical and randomized trials have been investigated. However, in a recent research review article it was hypothesized that pioglitazone could play a role in attenuating lung injury in COVID-19 patients (15) . Pioglitazone is another available thiazolidinedione that may inhibit the activation of NF-kB and MAPK pathways by reducing the expression of CARD9 in COVID-19 patients (15, 86) . Several reports have indicated that PPARg agonists could be candidates for modulating the cytokine storm in the COVID-19 disease (87, 149, 150) . A possible therapeutic role for pioglitazone has been identified with respect to the SARS-CoV-2 infection (16) . Pioglitazone can act as a 3CL-Pro inhibitor to downregulate SARS-CoV-2 RNA synthesis and replication (151) . More specifically, PPARg agonists can decrease the secretion of several pro-inflammatory cytokines, including TNF-a, IL-1, and IL-6, in both the monocytes and macrophages (152) . Recent studies have shown that numerous COVID-19 patients present hypertension and diabetes, whereas few patients present chronic obstructive-pulmonary diseases (153, 154) . Moreover, a recent meta-analysis showed that hypertension and diabetes were highly associated with comorbidities in COVID-19 patients (155). One of the major roles of PPARg agonists is to decrease TNF-a expression, the proportion of Th17 cells and NF-kB activity in order to repress inflammation (12) . Numerous inflammatory cytokines, chemokines, or intracellular pathways, such as TNF-a and IL-6, can downregulate PPARg expression, whereas in adipocytes, adiponectin increases PPARg expression and then downregulates the LPS-induced NF-ϰB expression and IL-6 production (156) . Pioglitazone suppresses inflammation by reducing TNF-a and MCP-1 expression, two important mediators of inflammation (157) . However, the use of PPARg agonists may have some side effects, even though newer molecules now have fewer disadvantages. The use of PPARg agonists may therefore increase cardiovascular events, despite numerous studies showing no significant increase in side effects (14) . In the rapidly evolving situation surrounding the COVID-19 pandemic, it is essential to better understand the different pathways involved in the disease. In the SARS-CoV-2 infection, the canonical WNT/b-catenin pathway seems to be upregulated in association with the TGF-b and STAT pathways, whereas both ACE2 and PPARg expression is downregulated, coupled with an increased number of pro-inflammatory markers. Since increased WNT/b-catenin pathway activity is associated with the increase of immune signaling and fibrosis processes, the inhibition of this pathway could result in the negative modulation of the SARS-CoV-2 infection. PPARg agonists provide inexpensive treatments that are commonly used around the globe. By directly targeting inflammation, ACE2 and the WNT/b-catenin pathway, PPARg agonists may well be prospective candidates for delivering SARS-CoV-2 therapy in clinical settings. All authors listed have made substantial, direct, and intellectual contributions to the work and approved it for publication. Evaluation, and Treatment of Coronavirus Clinical Characteristics of Coronavirus Disease 2019 in China Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression Tocilizumab for Severe Worsening COVID-19 Pneumonia: a Propensity Score Analysis Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease Pathological findings of COVID-19 associated with acute respiratory distress syndrome Lung Repair and Regeneration in ARDS: Role of PECAM1 and Wnt Signaling Wnt5a and Wnt11 as acute respiratory distress syndrome biomarkers for severe acute respiratory syndrome coronavirus 2 patients Alzheimer Disease: Crosstalk between the Canonical Wnt/Beta-Catenin Pathway and PPARs Alpha and Gamma Crosstalk Between Peroxisome Proliferator-Activated Receptor Gamma and the Canonical WNT/b-Catenin Pathway in Chronic Inflammation and Oxidative Stress During Carcinogenesis PPARg agonists: potential treatment for autism spectrum disorder by inhibiting the canonical WNT/b-catenin pathway Interplay between the renin-angiotensin system, the canonical WNT/b-catenin pathway and PPARg in hypertension Can pioglitazone be potentially useful therapeutically in treating patients with COVID-19? Use of pioglitazone in people with type 2 diabetes mellitus with coronavirus disease 2019 (COVID-19): Boon or bane? Clinical characteristics of 82 cases of death from COVID-19 Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools The Lung Macrophage in SARS-CoV-2 Infection: A Friend or a Foe? Front Immunol Can Beta-2-Adrenergic Pathway Be a New Target to Combat SARS-CoV-2 Hyperinflammatory Syndrome?-Lessons Learned From Cancer Severe respiratory SARS-CoV2 infection: Does ACE2 receptor matter Suppression of innate antiviral response by severe acute respiratory syndrome coronavirus M protein is mediated through the first transmembrane domain Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-kappaB signaling Commonalities Between COVID-19 and Radiation Injury Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China NF-kappaB and its regulation on the immune system Nucleocapsid protein of SARS-CoV activates interleukin-6 expression through cellular transcription factor NF-kappaB Inhibition of NF-kB-mediated inflammation in severe acute respiratory syndrome coronavirusinfected mice increases survival Severe acute respiratory syndrome coronavirus ORF3a protein activates the NLRP3 inflammasome by promoting TRAF3-dependent ubiquitination of ASC Combating sars-cov-2 through lipoxins, proteasome, caveolin and nuclear factor-kb pathways in non-pregnant and pregnant populations Generating Cellular Diversity and Spatial Form: Wnt Signaling and the Evolution of Multicellular Animals Eliminating Cancer Stem Cells by Targeting Embryonic Signaling Pathways Wnt/b-catenin signaling and disease Wnt signaling: role in Alzheimer disease and schizophrenia Crosstalk between Wnt/b-Catenin and NF-kB Signaling Pathway during Inflammation Targeting the Canonical WNT/b-Catenin Pathway in Cancer Treatment Using Non-Steroidal Anti-Inflammatory Drugs Wnt/b-Catenin Signaling Induces Integrin a4b1 in T Cells and Promotes a Progressive Neuroinflammatory Disease in Mice Wnt/b-catenin signaling in Alzheimer's disease Dysregulation of the Wnt pathway inhibits timely myelination and remyelination in the mammalian CNS Aberrant expression of b-catenin in CD4+ T cells isolated from primary progressive multiple sclerosis patients Wnt/b-catenin and its Diverse Physiological Cell Signaling Pathways in Neurodegenerative and Neuropsychiatric Disorders Wnt your brain be inflamed? Yes, it Wnt! Circadian rhythms, Wnt/ beta-catenin pathway and PPAR alpha/gamma profiles in diseases with primary or secondary cardiac dysfunction Opposite Interplay between PPAR Gamma and Canonical Wnt/Beta-Catenin Pathway in Amyotrophic Lateral Sclerosis Thermodynamics in Neurodegenerative Diseases: Interplay Between Canonical WNT/Beta-Catenin Pathway-PPAR Gamma, Energy Metabolism and Circadian Rhythms Parkinson's Disease: Potential Actions of Lithium by Targeting the WNT/b-Catenin Pathway, Oxidative Stress WNT/b-Catenin Pathway and PPARg in COVID-19 Identification of c-MYC as a target of the APC pathway The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway Proximal events in Wnt signal transduction Peroxisome proliferatoractivated receptor gamma activation can regulate beta-catenin levels via a proteasome-mediated and adenomatous polyposis coli-independent pathway Increased Dickkopf-1 expression in transgenic mouse models of neurodegenerative disease Interactions between TGF-b1, canonical WNT/b-catenin pathway and PPAR g in radiation-induced fibrosis Hypothesis of Opposite Interplay Between the Canonical WNT/beta-catenin Pathway and PPAR Gamma in Primary Central Nervous System Lymphomas b-catenin is a target for the ubiquitin-proteasome pathway GSK3: a multifaceted kinase in Wnt signaling GSK3 signalling in neural development The JNK-and AKT/GSK3b-Signaling Pathways Converge to Regulate Puma Induction and Neuronal Apoptosis Induced by Trophic Factor Deprivation Age-related neuroinflammation and changes in AKT-GSK-3b and WNT/ b-CATENIN signaling in rat hippocampus Wnt/ beta-catenin signaling induces the expression and activity of betaTrCP ubiquitin ligase receptor New perspectives on APC control of cell fate and proliferation in colorectal cancer Crosstalk between NF-kappaB/p65 and beta-catenin/TCF4/p300 signalling pathways through alterations in GSK-3beta expression during trans-differentiation of endometrial carcinoma cells Phosphorylation of serine 468 by GSK-3beta negatively regulates basal p65 NF-kappaB activity WNT signalling in the immune system: WNT is spreading its wings Early activation of pro-fibrotic WNT5A in sepsis-induced acute lung injury WNT ligands contribute to the immune response during septic shock and amplify endotoxemia-driven inflammation in mice Canonical and Non-Canonical Wnt Signaling in Immune Cells Wnt5A/CaMKII signaling contributes to the inflammatory response of macrophages and is a target for the antiinflammatory action of activated protein C and interleukin-10 Expression of WNT5A in Idiopathic Pulmonary Fibrosis and Its Control by TGF-b and WNT7B in Human Lung Fibroblasts Proteomic and Metabolomic Characterization of COVID-19 Targeting Interleukin-6 Signaling in Clinic Plasminogen Activator Inhibitor 1 Promotes Immunosuppression in Human Non-Small Cell Lung Cancers by Enhancing TGF-B1 Expression in Macrophage TGF-beta1-induced PAI-1 gene expression requires MEK activity and cell-to-substrate adhesion An aberrant STAT pathway is central to COVID-19 TGF-b1 -A truly transforming growth factor in fibrosis and immunity Repression of beta-catenin signaling by PPAR gamma ligands Suppression of canonical Wnt/beta-catenin signaling by nuclear plakoglobin recapitulates phenotype of arrhythmogenic right ventricular cardiomyopathy Peroxisomeproliferator-activated receptor gamma suppresses Wnt/beta-catenin signalling during adipogenesis SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target Role of Wnt4/b-catenin, Ang II/TGFb, ACE2, NF-kB, and IL-18 in attenuating renal ischemia/ reperfusion-induced injury in rats treated with Vit D and pioglitazone Ligand to PPARg, Improves Blood Pressure and Vascular Function through Renin-Angiotensin System Regulation COVID-19: is there a link between the course of infection and pharmacological agents in diabetes? Diabetes and Cardiovascular Disease (D&CVD) EASD Study Group. Issues of Cardiovascular Risk Management in People With Diabetes in the COVID-19 Era Role of oxidized LDL-induced "trained macrophages" in the pathogenesis of COVID-19 and benefits of pioglitazone: A hypothesis WNT/b-Catenin Pathway and PPARg in COVID-19 Pharmacological (or Synthetic) and Nutritional Agonists of PPAR-g as Candidates for Cytokine Storm Modulation in COVID-19 Disease TGF-b in fibrosis by acting as a conductor for contractile properties of myofibroblasts Regulation of the effects of TGF-beta 1 by activation of latent TGF-beta 1 and differential expression of TGF-beta receptors (T beta R-I and T beta R-II) in idiopathic pulmonary fibrosis DA-Raf-Mediated Suppression of the Ras-ERK Pathway Is Essential for TGF-b1-Induced Epithelial-Mesenchymal Transition in Alveolar Epithelial Type 2 Cells Severe acute respiratory syndromeassociated coronavirus nucleocapsid protein interacts with Smad3 and modulates transforming growth factor-beta signaling Mechanisms of Jak/STAT signaling in immunity and disease Cytokine Signaling in Tumor Progression The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells Interleukin-6: designing specific therapeutics for a complex cytokine Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19 Computationally predicted SARS-COV-2 encoded microRNAs target NFKB, JAK/STAT and TGFB signaling pathways Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors Monocyte-derived Alveolar Macrophages: The Dark Side of Lung Repair? Plasminogen activator inhibitor-1 stimulates macrophage activation through Toll-like Receptor-4 Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients A potential treatment of COVID-19 with TGF-b blockade Intermittent hypoxia mediated by TSP1 dependent on STAT3 induces cardiac fibroblast activation and cardiac fibrosis. eLife Targeting TGF-b Mediated SMAD Signaling for the Prevention of Fibrosis Nuclear receptors: nomenclature, ligands, mechanisms of their effects on gene expression An overview on biological mechanisms of PPARs Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells Regulation of cytokine expression by ligands of peroxisome proliferator activated receptors The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets Peroxisome proliferator-activated receptor (PPAR) gamma in cardiovascular disorders and cardiovascular surgery Pleiotropic effects of thiazolidinediones: taking a look beyond antidiabetic activity Gene Expression Changes Induced by PPAR Gamma Agonists in Animal and Human Liver Thermodynamic Aspects and Reprogramming Cellular Energy Metabolism during the Fibrosis Process Pioglitazone, a peroxisome proliferator-activated receptor gamma ligand, suppresses bleomycin-induced acute lung injury and fibrosis Role of adipocyte mitochondria in inflammation, lipemia and insulin sensitivity in humans: effects of pioglitazone treatment Pioglitazone inhibits the expression of inflammatory cytokines from both monocytes and lymphocytes in patients with impaired glucose tolerance Reduction of renal lipid content and proteinuria by a PPAR-g agonist in a rat model of angiotensin IIinduced hypertension Pioglitazone inhibits the secretion of proinflammatory cytokines and chemokines in astrocytes stimulated with lipopolysaccharide Pioglitazone attenuates lung injury by modulating adipose inflammation The role of pro-and anti-inflammatory responses in silica-induced lung fibrosis Peroxisome proliferatoractivated receptor-gamma: potential molecular therapeutic target for HIV-1-associated brain inflammation Pioglitazone treatment following spinal cord injury maintains acute mitochondrial integrity and increases chronic tissue sparing and functional recovery Anti-inflammatory effects of short-term pioglitazone therapy in men with advanced diabetic nephropathy WNT/b-Catenin Pathway and PPARg in COVID-19 Thermodynamics in Gliomas: Interactions between the Canonical WNT/Beta-Catenin Pathway and PPAR Gamma Inhibitory effects of PPARg ligands on TGF-b1-induced corneal myofibroblast transformation Transcription factor Snail is a novel regulator of adipocyte differentiation via inhibiting the expression of peroxisome proliferator-activated receptor g b-Catenin pathway is required for TGF-b1 inhibition of PPARg expression in cultured hepatic stellate cells Emerging role of the b-catenin-PPARg axis in the pathogenesis of colorectal cancer Opposite Interplay Between the Canonical WNT/b-Catenin Pathway and PPAR Gamma: A Potential Therapeutic Target in Gliomas Glycogen synthase kinase 3 is part of the molecular machinery regulating the adaptive response to LPS stimulation in microglial cells The Wnt/beta-catenin signaling pathway targets PPARgamma activity in colon cancer cells Functional interaction between peroxisome proliferator-activated receptor gamma and beta-catenin Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2 ACE2 Nascence, trafficking, and SARS-CoV-2 pathogenesis: the saga continues Angiotensin-converting enzyme II in the heart and the kidney The SARS-CoV-2 host cell receptor ACE2 correlates positively with immunotherapy response and is a potential protective factor for cancer progression ACE2 correlated with immune infiltration serves as a prognostic biomarker in endometrial carcinoma and renal papillary cell carcinoma: implication for COVID-19 The SARS-CoV-2 Spike Glycoprotein Biosynthesis, Structure, Function, and Antigenicity: Implications for the Design of Spike-Based Vaccine Immunogens Angiotensinconverting enzyme 2 is a functional receptor for the SARS coronavirus Cigarette Smoke Exposure and Inflammatory Signaling Increase the Expression of the SARS-CoV-2 Receptor ACE2 in the Respiratory Tract ACE2: from vasopeptidase to SARS virus receptor Primary role of angiotensin-converting enzyme-2 in cardiac production of angiotensin-(1-7) in transgenic Ren-2 hypertensive rats The pivotal link between ACE2 deficiency and SARS-CoV-2 infection Metabolic syndrome and COVID-19: An update on the associated comorbidities and proposed therapies Gamma-oryzanol as a potential modulator of oxidative stress and inflammation via PPAR-y in adipose tissue: a hypothetical therapeutic for cytokine storm in COVID-19? Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods PPAR-gamma activation as an anti-inflammatory therapy for respiratory virus infections Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan Prevalence of comorbidities and its effects in coronavirus disease 2019 patients: A systematic review and meta-analysis Adiponectin inhibits LPS-induced NF-kappaB activation and IL-6 production and increases PPARgamma2 expression in adipocytes Immunomodulatory therapy for severe influenza The authors thank Mr. Brian Keogh, PhD, for the proofreading of the manuscript.